Eplerenone in patients with systolic heart failure and mild symptoms

Zannad, Faiez, McMurray, John J.V., Krum, Henry, van Veldhuisen, Dirk J., Swedberg, Karl, Shi, Harry, Vincent, John, Pocock, Stuart J. +1 more·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1009492

Cited by (1,005)

Items 101–200 of 1,005

  1. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure
    Mihai Gheorghiade, Michael Böhm, Stephen John Greene, Gregg C. Fonarow, Eldrin Foster Lewis, Faiez M. Zannad, Scott David Solomon, Fabio Baschiera, Jaco Botha, Tsushung A. Hua et al. · 2013 · JAMA
  2. 2014 ESC/EACTS Guidelines on myocardial revascularization
    Stephan Windecker, Philippe H. Kolh, Fernándo Alfonso, Jean‐Philippe Collet, Jochen Cremer, Volkmar Falk, Gerasimos S Filippatos, Christian W. Hamm, Stuart J. Head, Peter Jüni et al. · 2015 · EuroIntervention
  3. Contemporary Cardiac Issues in Duchenne Muscular Dystrophy
    Elizabeth M. McNally, Jonathan R. Kaltman, D. Woodrow Benson, Charles E. Canter, Linda H. Cripe, Dongsheng Duan, Jonathan Daniel Finder, William J. Groh, Eric P. Hoffman, Daniel Philip Judge et al. · 2015 · Circulation
  4. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
    Maddox, Thomas M., Januzzi, James L., Allen, Larry A., Breathett, Khadijah, Brouse, Sara, Butler, Javed, Davis, Leslie L., Fonarow, Gregg C., Ibrahim, Nasrien E., Lindenfeld, JoAnn et al. · 2024 · Journal of the American College of Cardiology
  5. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
    Swedberg, Karl, Zannad, Faiez, McMurray, John J.V., Krum, Henry, van Veldhuisen, Dirk J., Shi, Harry, Vincent, John, Pitt, Bertram · 2012 · Journal of the American College of Cardiology
  6. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial
    Rienstra, Michiel, Hobbelt, Anne H, Alings, Marco, Tijssen, Jan G P, Smit, Marcelle D, Brügemann, Johan, Geelhoed, Bastiaan, Tieleman, Robert G, Hillege, Hans L, Tukkie, Raymond et al. · 2018 · European Heart Journal
  7. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma
    Fernandes-Rosa, Fabio Luiz, Williams, Tracy Ann, Riester, Anna, Steichen, Olivier, Beuschlein, Felix, Boulkroun, Sheerazed, Strom, Tim M., Monticone, Silvia, Amar, Laurence, Meatchi, Tchao et al. · 2014 · Hypertension
  8. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment
    Massimo Volpe, M Carnovali, Vittoria Mastromarino · 2015 · Clinical Science
  9. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association
    Brian Feingold, William T. Mahle, Scott R. Auerbach, Paula R. Clemens, Andrea A. Domenighetti, John L. Jefferies, Daniel Philip Judge, Ashwin K. Lal, Larry Wayne Markham, W. James Parks et al. · 2017 · Circulation
  10. Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation
    Gianluigi Savarese, Takuya Kishi, Orly Vardeny, Samuel Adamsson Eryd, Johan Bodegård, Lars H. Lund, Marcus Thuresson, Biykem Bozkurt · 2022 · JACC Heart Failure
  11. Sympathetically Mediated Changes in Capacitance
    Catherine Chelimsky-Fallick, Paul A. Sobotka, Mark E. Dunlap · 2011 · Circulation Heart Failure
  12. Targeting inflammation in metabolic syndrome
    Welty, Francine K., Alfaddagh, Abdulhamied, Elajami, Tarec K. · 2016 · Translational Research
  13. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
    McDonald, Michael, Virani, Sean, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L., Lepage, Serge et al. · 2021 · Canadian Journal of Cardiology
  14. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
    Clyde W. Yancy, Mariell L Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara B. Horwich, James L. Januzzi et al. · 2013 · Journal of the American College of Cardiology
  15. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
    Filippatos, Gerasimos, Anker, Stefan D., Agarwal, Rajiv, Ruilope, Luis M., Rossing, Peter, Bakris, George L., Tasto, Christoph, Joseph, Amer, Kolkhof, Peter, Lage, Andrea et al. · 2022 · Circulation
  16. Hallmarks of cardiovascular ageing
    Mahmoud Abdellatif, Peter P. Rainer, Simon Sedej, Guido Kroemer · 2023 · Nature Reviews Cardiology
  17. Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction
    Akshay Suvas Desai, Eldrin Foster Lewis, Rebecca Li, Scott David Solomon, Susan F. Assmann, Robin Boineau, Nadine Clausell, Rafael Díaz, Jerome L. Fleg, И. Г. Гордеев et al. · 2011 · American Heart Journal
  18. Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure
    Orly Vardeny, Dong Hong Wu, Akshay Suvas Desai, Patrick Rossignol, Faiez M. Zannad, Bertram Pitt, Scott David Solomon · 2012 · Journal of the American College of Cardiology
  19. Diuretic response in acute heart failure—pathophysiology, evaluation, and therapy
    Jozine M. ter Maaten, Mattia A. E. Valente, Kevin Damman, Hans L. Hillege, Gerjan J Navis, Adriaan A. Voors · 2015 · Nature Reviews Cardiology
  20. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches
    Stephane R B Heymans, Neal K. Lakdawala, Carsten Tschöpe, Karin Klingel · 2023 · The Lancet
  21. Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
    Lars Bärfacker, Alexander Kühl, Alexander Hillisch, Rolf Grosser, Santiago Figueroa‐Pérez, Heike Heckroth, Adam Nitsche, Jens‐Kerim Ergüden, Heike Gielen‐Haertwig, Karl‐Heinz Schlemmer et al. · 2012 · ChemMedChem
  22. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
    Molitch, Mark E., Adler, Amanda I., Flyvbjerg, Allan, Nelson, Robert G., So, Wing-Yee, Wanner, Christoph, Kasiske, Bertram L., Wheeler, David C., de Zeeuw, Dick, Mogensen, Carl E. · 2015 · Kidney International
  23. The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy
    Stella Styliani Daskalopoulou, Nadia A. Khan, Robert Ross Quinn, Marcel Ruzicka, Donald W. McKay, Daniel G. Hackam, Simon W. Rabkin, Doreen M. Rabi, Richard E. Gilbert, Raj S. Padwal et al. · 2012 · Canadian Journal of Cardiology
  24. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
    Peter Kolkhof, Lars Bärfacker · 2017 · Journal of Endocrinology
  25. The Prevention of Hospital Readmissions in Heart Failure
    Boback Ziaeian, Gregg C. Fonarow · 2015 · Progress in Cardiovascular Diseases
  26. Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy
    Patrick Rossignol, Daniela Dobre, John J.V. McMurray, Karl B Swedberg, Henry Krum, Dirk Jan van Veldhuisen, Harry H. Shi, Michael Messig, John Vincent, Nicolas Girerd et al. · 2013 · Circulation Heart Failure
  27. Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases
    Johann K Bauersachs, Frédéric Jaisser, Robert D. Toto · 2014 · Hypertension
  28. Treatment of Hypertension in Patients With Coronary Artery Disease
    Clive Rosendorff, Daniel T. Lackland, Matthew Allison, Wilbert S. Aronow, Henry R. Black, Roger Scott Blumenthal, Christopher Paul Cannon, James A. de Lemos, W.J. Elliott, Laura Findeiss et al. · 2015 · Circulation
  29. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial
    Subha V. Raman, Kan N. Hor, Wojciech M. Mazur, Nancy J. Halnon, John T. Kissel, Xin He, Tam Tran, Suzanne Smart, Beth McCarthy, Michael D. Taylor et al. · 2014 · The Lancet Neurology
  30. Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function
    Romain Eschalier, John J.V. McMurray, Karl B Swedberg, Dirk Jan van Veldhuisen, Henry Krum, Stuart Pocock, Harry H. Shi, John Vincent, Patrick Rossignol, Faiez M. Zannad et al. · 2013 · Journal of the American College of Cardiology
  31. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
    Jun Ma, Yanan Li, Xiangyu Yang, Kai Liu, Xin Zhang, Xianghao Zuo, Runyu Ye, Ziqiong Wang, Rufeng Shi, Qingtao Meng et al. · 2023 · Signal Transduction and Targeted Therapy
  32. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction
    Michael M. Givertz, Lynne Warner Stevenson, Maria Rosa Costanzo, Robert C. Bourge, Jordan G. Bauman, Greg Ginn, William T. Abraham · 2017 · Journal of the American College of Cardiology
  33. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
    Burnett, Heather, Earley, Amy, Voors, Adriaan A., Senni, Michele, McMurray, John J.V., Deschaseaux, Celine, Cope, Shannon · 2017 · Circulation Heart Failure
  34. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
  35. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
    Zannad, Faiez, Garcia, Angeles Alonso, Anker, Stefan D., Armstrong, Paul W., Calvo, Gonzalo, Cleland, John G.F., Cohn, Jay N., Dickstein, Kenneth, Domanski, Michael J., Ekman, Inger et al. · 2013 · European Journal of Heart Failure
  36. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
    Javed Butler, Stefan D. Anker, Lars H. Lund, Andrew J.S. Coats, Gerasimos S Filippatos, Tariq Jamal Siddiqi, Tim Friede, Vincent Fabien, Mikhail Kosiborod, Marco Metra et al. · 2022 · European Heart Journal
  37. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
    Gregg C. Fonarow, Clyde W. Yancy, Adrian F. Hernandez, Eric David Peterson, John A. Spertus, Paul A. Heidenreich · 2011 · American Heart Journal
  38. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
    Milton Packer · 2017 · Circulation
  39. Aldosterone as a Mediator of Cardiovascular Damage
    Fabrizio Buffolo, Martina Tetti, Paolo Mulatero, Silvia Monticone · 2022 · Hypertension
  40. Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure Registry
    Gianluigi Savarese, Juan Jesús Carrero, Bertram Pitt, Stefan D. Anker, Giuseppe M.C. Rosano, Ulf Dahlström, Lars H. Lund · 2018 · European Journal of Heart Failure
  41. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
    Iris E. Beldhuis, Carolyn S.P. Lam, Jeffrey M. Testani, Adriaan A. Voors, Harriette G.C. Van Spall, Jozine M. ter Maaten, Kevin Damman · 2022 · Circulation
  42. Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations
    Rogers, Jennifer K., McMurray, John J.V., Pocock, Stuart J., Zannad, Faiez, Krum, Henry, van Veldhuisen, Dirk J., Swedberg, Karl, Shi, Harry, Vincent, John, Pitt, Bertram · 2012 · Circulation
  43. Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
    Calhoun, David A., White, William B., Krum, Henry, Guo, Weinong, Bermann, Georgina, Trapani, Angelo, Lefkowitz, Martin P., Ménard, Joël · 2011 · Circulation
  44. Gender medicine: a task for the third millennium
    Giovannella Baggio, Alberto Corsini, Annarosa Floreani, Sandro Giannini, Vittorina Zagonel · 2013 · Clinical Chemistry and Laboratory Medicine (CCLM)
  45. Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
    Yoshihiro Matsumoto, Yasuo Mori, Shinji Kageyama, Kazuo Arihara, Toshikazu Sugiyama, Hiromichi Ohmura, Toru Yakushigawa, Hatsumi Sugiyama, Yasushi Shimada, Y Nojima et al. · 2013 · Journal of the American College of Cardiology
  46. 2024 Clinical practice guidelines for Hypertension in adults
    Ж. Д. Кобалава, А. О. Конради, Sergey Vladimirovich Nedogoda, Evgeny V. Shlyakhto, G. P. Arutyunov, Е. И. Баранова, О. Л. Барбараш, N. V. Bobkova, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
  47. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril
    Akshay Suvas Desai, Orly Vardeny, Brian Lee Claggett, John J.V. McMurray, Milton Packer, Karl B Swedberg, Jean Lucien Rouleau, Michael R. Zile, Martin P. Lefkowitz, Victor Chengwei Shi et al. · 2016 · JAMA Cardiology
  48. Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
    Marcello A. Tonelli, S. Ananth Karumanchi, Ravi Thadhani · 2016 · Circulation
  49. Recovered Heart Failure with Reduced Ejection Fraction and Outcomes: A Prospective Study
    Josep Lupón, Carles Díez‐López, Marta de Antonio, Mar Domingo, Elisabet Zamora, Pedro Moliner, Beatriz González, Javier Santesmases, María Isabel Troya, Antoni Bayés‐Genís · 2017 · European Journal of Heart Failure
  50. Comorbidity of atrial fibrillation and heart failure
    Liang‐Han Ling, Peter M. Kistler, Jonathan M. Kalman, RICHARD JOHN SCHILLING, Ross Jacob Hunter · 2015 · Nature Reviews Cardiology
  51. Racial and ethnic disparities in heart failure: current state and future directions
    Sabra C. Lewsey, Khadijah K Breathett · 2021 · Current Opinion in Cardiology
  52. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research
    Freemantle, N., Marston, L., Walters, K., Wood, J., Reynolds, M. R., Petersen, I. · 2013 · BMJ
  53. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
    Martinez, Felipe A., Serenelli, Matteo, Nicolau, Jose C., Petrie, Mark C., Chiang, Chern-En, Tereshchenko, Sergey, Solomon, Scott D., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N. et al. · 2020 · Circulation
  54. 2024 Clinical practice guidelines for Chronic heart failure
    Albert S. Galyavich, Sergey N. Tereshchenko, T. M. Uskach, Fail T. Ageev, D. M. Aronov, G. P. Arutyunov, Yu. L. Begrambekova, Yu. N. Belenkov, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
  55. Myocardial Extracellular Volume by Cardiac Magnetic Resonance Imaging in Patients Treated With Anthracycline-Based Chemotherapy
    Tomas G. Neilan, Otávio R. Coelho‐Filho, Ravi V. Shah, Jiazuo H. Feng, Diego Pena-Herrera, Damien Mandry, François Pierre-Mongeon, Bobak Heydari, Sanjeev A Francis, Javid J. Moslehi et al. · 2012 · The American Journal of Cardiology
  56. Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist
    Orly Vardeny, Brian Lee Claggett, Inder S. Anand, Patrick Rossignol, Akshay Suvas Desai, Faiez M. Zannad, Bertram Pitt, Scott David Solomon · 2014 · Circulation Heart Failure
  57. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction
    Scott David Solomon, Brian Lee Claggett, Akshay Suvas Desai, Milton Packer, Michael R. Zile, Karl B Swedberg, Jean Lucien Rouleau, Victor Chengwei Shi, Randall C. Starling, Ömer Kozan et al. · 2016 · Circulation Heart Failure
  58. The Renin-Angiotensin-Aldosterone System and Heart Failure
    GABRIEL T. SAYER, Geetha Bhat · 2013 · Cardiology Clinics
  59. A Systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: Rationale, Design, and Baseline Characteristics of BIOSTAT-CHF
    Adriaan A. Voors, Stefan D. Anker, John G.F. Cleland, Kenneth Dickstein, Gerasimos S Filippatos, Pim van der Harst, Hans L. Hillege, Chim Choy Lang, Jozine M. ter Maaten, Leong L. Ng et al. · 2016 · European Journal of Heart Failure
  60. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies
    Wilfried Müllens, Frederik Hendrik Verbrugge, Petra Nijst, W.H. Wilson Tang · 2017 · European Heart Journal
  61. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction
    Miranda E. Merrill, Nancy K. Sweitzer, JoAnn Lindenfeld, David Peter Kao · 2019 · JACC Heart Failure
  62. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Circulation Journal
  63. 2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension
    Chern‐En Chiang, Tzung‐Dau Wang, Kwo-Chang Ueng, Tsung‐Hsien Lin, Hung‐I Yeh, Chung-Yin Chen, Yih-Jer Wu, Wei‐Chuan Tsai, Ting‐Hsing Chao, Chen-Huan Chen et al. · 2014 · Journal of the Chinese Medical Association
  64. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
    Kieran F. Docherty, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr P. Ponikowski, David L. DeMets, Marc Steven Sabatine, Olof Bengtsson et al. · 2020 · European Heart Journal
  65. Peripartum cardiomyopathy
    Michael C. Honigberg, Michael M. Givertz · 2019 · BMJ
  66. Nurse staffing, medical staffing and mortality in Intensive Care: An observational study
    Elizabeth West, David Barron, David A Harrison, Anne Marie Rafferty, Kathy Rowan, Colin F. B. Sanderson · 2014 · International Journal of Nursing Studies
  67. Incidence, Predictors and Clinical Management of Hyperkalaemia in New Users of Mineralocorticoid Receptor Antagonists
    Marco Trevisan, Pietro de Deco, Hairong Xu, Marie Evans, Bengt Lindholm, Rino Bellocco, Peter F. Barany, Tomas Jernberg, Lars H. Lund, Juan Jesús Carrero · 2018 · European Journal of Heart Failure
  68. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure
    Prins, Kurt W., Neill, John M., Tyler, John O., Eckman, Peter M., Duval, Sue · 2015 · JACC: Heart Failure
  69. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
    Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito et al. · 2021 · Circulation Journal
  70. Challenges, solutions and future directions in the evaluation of service innovations in health care and public health
    Rosalind Raine, Ray M. Fitzpatrick, Helen Barratt, Gywn Bevan, Nick A. Black, Ruth Boaden, Peter Bower, Marion Campbell, Jean‐Louis Denis, Kelly J. Devers et al. · 2016 · Health Services and Delivery Research
  71. Clinical Management of Hyperkalemia
    Biff F. Palmer, Juan Jesús Carrero, Deborah J. Clegg, Gates B. Colbert, Michael Emmett, Steven N. Fishbane, Debra J. Hain, Edgar V. Lerma, Macaulay A C Onuigbo, Anjay Rastogi et al. · 2020 · Mayo Clinic Proceedings
  72. The hypertension of Cushing's syndrome
    Andrea Maria Isidori, Chiara Graziadio, Rosa Maria Paragliola, Alessia Cozzolino, Alberto Giacinto Ambrogio, Annamaria Colao, Salvatore Maria Corsello, Rosario Pivonello · 2014 · Journal of Hypertension
  73. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study
    Cecilia Marianne Linde, Michael Robert Gold, William T. Abraham, Martin St. John Sutton, Stefano Ghio, Jeff Cerkvenik, Jean‐Claude Daubert, on behalf of the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group · 2013 · European Heart Journal
  74. Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial
    Sanjiv Jayendra Shah, John F. Heitner, Nancy K. Sweitzer, Inder S. Anand, Hae-Young Kim, Brian J. Harty, Robin Boineau, Nadine Clausell, Akshay Suvas Desai, Rafael Díaz et al. · 2012 · Circulation Heart Failure
  75. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
    Kolkhof, Peter, Jaisser, Frederic, Kim, So-Young, Filippatos, Gerasimos, Nowack, Christina, Pitt, Bertram · 2016 · Handbook of Experimental Pharmacology
  76. Mineralocorticoid receptors in vascular function and disease
    Amy McCurley, Iris Zamir Jaffe · 2011 · Molecular and Cellular Endocrinology
  77. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
    Faiez M. Zannad, Wendy Gattis Stough, Patrick Rossignol, Johann Bauersachs, John J.V. McMurray, Karl B Swedberg, Allan D. Struthers, A.A. Voors, Luis Miguel Ruilope, George L. Bakris et al. · 2012 · European Heart Journal
  78. Baseline Characteristics and Treatment of Patients in Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
    John J.V. McMurray, Milton Packer, Akshay Suvas Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Lucien Rouleau, Victor Chengwei Shi, Scott David Solomon, Karl B Swedberg et al. · 2014 · European Journal of Heart Failure
  79. Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
    Islam Y. Elgendy, Dhruv Mahtta, Carl J. Pepine · 2019 · Circulation Research
  80. Treatment of Hypertension in Patients With Coronary Artery Disease
    Clive Rosendorff, Daniel T. Lackland, Matthew Allison, Wilbert S. Aronow, Henry R. Black, Roger Scott Blumenthal, Christopher Paul Cannon, James A. de Lemos, W.J. Elliott, Laura Findeiss et al. · 2015 · Hypertension
  81. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
    Jackson, Alice M., Dewan, Pooja, Anand, Inder S., Bělohlávek, Jan, Bengtsson, Olof, de Boer, Rudolf A., Böhm, Michael, Boulton, David W., Chopra, Vijay K., DeMets, David L. et al. · 2020 · Circulation
  82. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction
    Takehiro Yamaguchi, Yasukatsu Izumi, Yasuhiro Nakamura, Takanori Yamazaki, Masayuki Shiota, Soichi Sano, Masako Tanaka, Mayuko Osada‐Oka, Kenei Shimada, Katuyuki Miura et al. · 2014 · International Journal of Cardiology
  83. Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
    Ulrich Kintscher, George L. Bakris, Peter Kolkhof · 2021 · British Journal of Pharmacology
  84. The Kidney in Congestive Heart Failure: ‘are Natriuresis, Sodium, and Diuretics Really the Good, the Bad and the Ugly?’
    Frederik Hendrik Verbrugge, Matthias Dupont, Paul Steels, Lars Grieten, Q. Swennen, W.H. Wilson Tang, Wilfried Müllens · 2013 · European Journal of Heart Failure
  85. Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure
    Harsh B. Golwala, Ambarish Pandey, Christine Ju, Javed Butler, Clyde W. Yancy, Deepak L. Bhatt, Adrian F. Hernandez, Gregg C. Fonarow · 2015 · Journal of the American College of Cardiology
  86. Pulseless Electric Activity
    Robert J. Myerburg, Henry R. Halperin, Debra Egan, Robin Boineau, Sumeet S. Chugh, Anne M. Gillis, Joshua I. Goldhaber, David A. Lathrop, Peter Xiaoping Liu, James T. Niemann et al. · 2013 · Circulation
  87. The Role of Aldosterone in Obesity-Related Hypertension
    Wakako Kawarazaki, Toshiro Fujita · 2016 · American Journal of Hypertension
  88. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
    João Pedro Ferreira, Faiez M. Zannad, Stuart Pocock, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Martina Brueckmann, Waheed Jamal, Dominik Steubl, Elke Schueler et al. · 2021 · Journal of the American College of Cardiology
  89. Diuretics
    George C. Roush, Ramdeep Kaur, Michael E. Ernst · 2013 · Journal of Cardiovascular Pharmacology and Therapeutics
  90. Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
    Lazich, Ivana, Bakris, George L. · 2014 · Seminars in Nephrology
  91. The science of steroids
    Timothy James Cole, Kelly Short, Stuart B. Hooper · 2019 · Seminars in Fetal and Neonatal Medicine
  92. Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension
    Ernesto Martínez‐Martínez, Laurent Calvier, Amaya Fernández‐Celis, Elodie Rousseau, Raquel Jurado-López, Luciana Venturini Rossoni, Frédéric Jaisser, Faiez M. Zannad, Patrick Rossignol, Victoria Cachofeiro et al. · 2015 · Hypertension
  93. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis
    Ali Albasri, Miriam Hattle, Constantinos Koshiaris, Anna V. Dunnigan, Ben Paxton, Sarah Emma Fox, Margaret C Smith, Lucinda Archer, Brooke Levis, Rupert Payne et al. · 2021 · BMJ
  94. Conventional heart failure therapy in cardiac ATTR amyloidosis
    Adam Ioannou, Paolo Massa, Rishi K Patel, Yousuf Razvi, Aldostefano Porcari, Muhammad Umaid Rauf, Anita Jiang, Giacomo Cabras, Stefano Filisetti, Roos Eline Bolhuis et al. · 2023 · European Heart Journal
  95. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials
    Catherine L. Tacon, John McCaffrey, Anthony P. Delaney · 2011 · Intensive Care Medicine
  96. Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
    Milton Packer, John J.V. McMurray · 2021 · European Journal of Heart Failure
  97. Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction
    Patrick Rossignol, John G.F. Cleland, Sunil Bhandari, Stéphane Tala, Finn Gustafsson, Renaud Fay, Zohra Lamiral, Daniela Dobre, Bertram Pitt, Faiez M. Zannad · 2011 · Circulation
  98. Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors
    Bertram Pitt, George L. Bakris, David A. Bushinsky, Dahlia Garza, Martha R. Mayo, Yuri Stasiv, Heidi Christ‐Schmidt, Lance Berman, Matthew R. Weir · 2015 · European Journal of Heart Failure
  99. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
    Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito et al. · 2021 · Journal of Cardiac Failure
  100. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
    Pardeep S. Jhund, Atefeh Talebi, Alasdair David Henderson, Brian Lee Claggett, Muthiah Vaduganathan, Akshay Suvas Desai, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv Jayendra Shah et al. · 2024 · The Lancet